Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.

NCT04247165 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer

Interventions

DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: Nivolumab
DRUG: Ipilimumab
RADIATION: SBRT

Sponsor

Herlev Hospital